Efficacy and Safety of CONAN® Proctological Cream for Treatment of Haemorrhoidal Disease
Hemorrhoid Pain, Haemorrhoid Inflammation
About this trial
This is an interventional treatment trial for Hemorrhoid Pain focused on measuring Haemorrhoids; anal fissures; controlled clinical trial.
Eligibility Criteria
Inclusion Criteria: Aged between 18 and 70 years Hemorrhoidal pathology, anal fissures and anitis NRS score ≥ 3 for at least one of the symptoms (burning, itching, feeling of heaviness, foreign body) Exclusion Criteria: Known hypersensitivity to study products Proctitis Current therapy with other local treatments based on phlebotropes and/or anti-inflammatories Surgical treatments undergone less than a year after inclusion Pregnancy, breastfeeding
Sites / Locations
- Policlinico Tor Vergata Foundation (PTV)
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Group A
Group B
Active treatment CONAN® (Medical Device, Omikron Italia Srl) a proctological cream containing 2.5% glycerin macerate from horse chestnut buds (escin), 1% hesperidin, 0.1% hyaluronic acid, 0.1% centella asiatica and 2.5% glycerinic extract of mallow; Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
No intervention. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.